Unique ID issued by UMIN | UMIN000016075 |
---|---|
Receipt number | R000018484 |
Scientific Title | Development and evaluation of the effectiveness of an Internet-based cognitive behavioral relapse prevention program for people with drug use problems: a multicenter study |
Date of disclosure of the study information | 2015/01/05 |
Last modified on | 2020/01/01 12:01:00 |
Development and evaluation of the effectiveness of an Internet-based cognitive behavioral relapse prevention program for people with drug use problems: a multicenter study
Effectiveness of a web-based cognitive behavioral relapse prevention program for people with drug use problems: a multicenter randomized controlled trial
Development and evaluation of the effectiveness of an Internet-based cognitive behavioral relapse prevention program for people with drug use problems: a multicenter study
Effectiveness of a web-based cognitive behavioral relapse prevention program for people with drug use problems: a multicenter randomized controlled trial
Japan |
Substance use disorder/ Substance abuse or dependence (psychoactive substances other than alcohol and tobacco)
Psychiatry |
Others
NO
The objective of this study is to examine the effectiveness of a web-based cognitive behavioral relapse prevention program in assisting individuals who wish to address drug use problems. We hypothesized that at the 8th, 20th and 32nd week of the follow-up assessment, the intervention group will report lower relapse risk and a longer period of abstinent days, compared to a control group that only received web-based self-monitoring.
Efficacy
Confirmatory
Pragmatic
Not applicable
1) Relapse risk (assessed by the Stimulant Relapse Risk Scale) assessment at the 8th (immediately after intervention), 20th and 32nd week after start of intervention
2) The longest period of abstinent days from primary abused drug during the 56-day intervention period (assessed by self-reports using the self-monitoring calendar)
1)-10) at assessments in the 8th (immediately after intervention), 20th and 32nd week after start of intervention
1) Motivation toward treatment and behavioral change (assessed by the Stage of Change Readiness and Treatment Eagerness Scale 8D)
2) Confidence in dealing with drug use cravings (assessed by Self-efficacy Scale for Drug Dependence)
3) Percentage of days abstinent from primary abused drug in the past 28 or 56 days (assessed by self-reports using the self-monitoring calendar or the Timeline Follow-back method)
4) Changes in the period of abstinent days from primary abused drug in the past 28 days (assessed by self-reports using the self-monitoring calendar or the Timeline Follow-Back method)
5) Expenses for drugs or alcohol in the last month
6) Retention in outpatient treatment (yes or no)
7) Involvement in self-help groups (yes or no)
8) Use of rehabilitation facilities (yes or no)
9) Health related QOL (assessed by WHOQOL26)
10) Sense of coherence (assessed by 3-item sense of coherence scale)
11) At baseline and 32-week follow-up assessment, psychiatric medical cost in the past 6 months (self-reported period and frequency of hospitalization, outpatient visit, prescription and group therapy).
Interventional
Parallel
Randomized
Individual
Open -but assessor(s) are blinded
Active
NO
NO
Institution is considered as a block.
YES
Central registration
2
Treatment
Behavior,custom |
A weekly 6-session web-based cognitive behavioral relapse prevention program (about 60 minutes per session), web-based day-by-day self-monitoring, provision of relevant information, and usual outpatient treatment for 8 weeks.
Web-based day-by-day self-monitoring, provision of relevant information, and usual outpatient treatment for 8 weeks.
20 | years-old | <= |
Not applicable |
Male and Female
1) Outpatients who were diagnosed with substance use disorder (abuse or dependence) assessed by DSM-IV or V (psychoactive substances other than alcohol and tobacco)
2) Those who used a primary abused drug in the past year
3) Those with access to the Internet via PC, smartphone or tablet computer and can exchange e-mail.
1) Patients with severe physical diseases
2) Patients with high suicide risk
3) Patients with severe symptoms of substance-induced psychotic disorder
4) Patients with impaired cognitive function
5) Those judged ineligible to participate in the study by a psychiatrist.
200
1st name | Norito |
Middle name | |
Last name | Kawakami |
Graduate School of Medicine, The University of Tokyo
Department of Mental Health
113-0033
7-3-1, Hongo, Bunkyuo-ku, Tokyo
0358413522
ayumi-takano@umin.ac.jp
1st name | Ayumi |
Middle name | |
Last name | Takano |
Graduate School of Medicine, The University of Tokyo
Department of Psychiatric Nursing
1130033
7-3-1 Hongo, Bunkyo-ku, Tokyo, Japan
03-5841-3522
ayumi-takano@umin.ac.jp
Department of Psychiatric Nursing, Graduate School of Medicine, The University of Tokyo
Pfizer Health Research Foundation
Non profit foundation
Japan
The Ethics Committee of the Faculty of Medicine and Graduate School of Medicine of the University of Tokyo
7-3-1 Hongo, Bunkyo-ku, Tokyo
03-5841-0818
ethics@m.u-tokyo.ac.jp
NO
国立精神・神経医療研究センター病院(東京都)、埼玉県立精神医療センター(埼玉県)、神奈川県立精神医療センター(神奈川県)、岡山県精神科医療センター(岡山県)、東京都立松沢病院(東京都)、アパリクリニック(東京都)
2015 | Year | 01 | Month | 05 | Day |
Unpublished
Main results already published
2014 | Year | 12 | Month | 27 | Day |
2012 | Year | 10 | Month | 11 | Day |
2015 | Year | 01 | Month | 13 | Day |
2016 | Year | 11 | Month | 20 | Day |
2014 | Year | 12 | Month | 28 | Day |
2020 | Year | 01 | Month | 01 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000018484